Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Kalaris Therapeutics (KLRS) Operating Expenses (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Operating Expenses data on record, last reported at $25.4 million in Q4 2020.

  • For Q4 2020, Operating Expenses rose 167.4% year-over-year to $25.4 million; the TTM value through Dec 2020 reached $71.3 million, changed N/A, while the annual FY2024 figure was $65.4 million, 67.26% down from the prior year.
  • Operating Expenses reached $25.4 million in Q4 2020 per KLRS's latest filing, up from $23.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $25.4 million in Q4 2020 and bottomed at $3.2 million in Q2 2019.